Abstract Background Hypoxia-inducible factor 2α (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and metastasis. Casdatifan is a potent, selective, orally bioavailable HIF-2α inhibitor that has demonstrat...
R. McKay, J. Merchan, A. Patnaik et al.· The Oncologist· 0 citations
Macrophages can adopt diverse functional states in response to environmental cues, a process that is fundamentally controlled at the level of transcriptional regulation. In this review, we outline a hierarchical framework of transcription factor activity that underpins macrophage identity and activation. Firstly, linea...
A. Drakaki, Josje M. A. Huisman, Marten A. Hoeksema· EMBO Journal· 0 citations
The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.
S. Srour, J. Chahoud, A. Drakaki et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.